Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056487 | 0.86 | HRH3 (0.49) | HRH3HRH4FFAR1FFAR4 | |
| SCHEMBL14439403 | 0.81 | HRH3 (0.57) | HRH3HRH4ALDH1A1TDP1FFAR1 | |
| SCHEMBL31525765 | 0.78 | HRH3 (0.54) | HRH3ALDH1A1HPGDCYP19A1KDM4E | |
| SCHEMBL16232108 | 0.78 | HRH3 (0.54) | HRH3ALDH1A1CYP19A1KDM4ETDP1 | |
| SCHEMBL29303937 | 0.78 | HRH3 (0.54) | HRH3ALDH1A1CYP19A1KDM4ETDP1 | |
| SCHEMBL20651133 | 0.78 | HRH3 (0.42) | HRH3HRH4ALDH1A1MAPT | |
| SCHEMBL5536594 | 0.77 | MEN1 (0.50) | HRH3HRH4ALDH1A1HPGDKDM4E | |
| SCHEMBL5536590 | 0.77 | HRH3 (0.41) | HRH3HRH4ALDH1A1KDM4ETDP1 | |
| SCHEMBL17193927 | 0.77 | AKR1B1 (0.46) | HRH3HRH4MAPT | |
| SCHEMBL16062592 | 0.77 | HRH3 (0.62) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | HRH3 92/4885HRH4 208/4885ALDH1A1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.